Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-nectin-4 antibody-drug conjugate LY4101174

An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) Fcg-silent monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4) conjugated, via maleimide-beta-glucuronide poly-sarcosine linkers, to the camptothecin analog and topoisomerase 1 inhibitor exatecan, with potential antineoplastic activity. Upon administration of the anti-nectin-4 ADC LY4101174, the anti-nectin-4 antibody targets and binds to nectin-4 expressed on tumor cells. Upon binding and internalization, exatecan is released. Exatecan inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of nectin-4-expressing tumor cells. Nectin-4, a TAA belonging to the nectin family, is overexpressed in a variety of cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-nectin-4 ADC LY4101174
anti-nectin-4/exatecan ADC LY4101174
Code name:ETx 22
ETx-22
ETx22
LY 4101174
LY-4101174
LY4101174
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search